<DOC>
	<DOCNO>NCT02831842</DOCNO>
	<brief_summary>This non-interventional study meta-analyze overall survival outcome among participant metastatic colorectal cancer ( mCRC ) available V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog ( KRAS ) status , receive firstline treatment bevacizumab contain treatment regimen routine clinical practice . The study leverage secondary data exist cohort United Stats America ( USA ) , Germany , Australia , Denmark .</brief_summary>
	<brief_title>A Real World Study Evaluate Effectiveness Avastin ( Bevacizumab ) First Line Treatment Patients With Metastatic Colorectal Cancer Known KRAS Status</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Participants metstatic colorectal cancer ( mCRC ) diagnose point prior March 2014 ( United States [ US ] Vector Oncology Protocol Sponsored US Roche Pharma Medical Affairs ) , diagnose September 2006 March 2015 ( Germany Tumourregister Kolorektales Karzinom [ TKK ] Registry Study Supported German Roche Pharma Affiliate ) , diagnose September 2009 December 2014 ( Australia Treatment Recurrent Advanced Colorectal Cancer [ TRACC ] Registry Supported Roche Pharma Australia ) , diagnose 2009 2013 ( Denmark Roche Diagnostic Sponsored Study Aarhus University Hospital , Department Clinical Epidemiology ) Participants treat first line bevacizumab AntiEGFR treatment regimen chemotherapy alone Participants available data overall survival ( OS ) , KRAS test status , left/right tumor location status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>